Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer

NCT00343109 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00343109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
Not reported
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, male breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer